DERMATOLOGY RESEARCH FELLOW, UNIVERSITY OF SYDNEY
Posted 3 years ago
The project is an NHMRC-funded Phase 3 randomised controlled trial to investigate the effects of oral nicotinamide (vitamin B3) on nonmelanoma skin cancer incidence in immune suppressed transplant recipients. Nicotinamide prevents sunlight-induced immune suppression in the skin, enhances DNA repair and has significantly reduced premalignant actinic keratoses and skin cancers in Phase 2 and Phase 3 randomised controlled trials in immune competent individuals. This multicentre Australian trial now aims to determine the efficacy and tolerability of nicotinamide in transplant patients.
The successful applicant will be 0.2 FTE based at Royal Prince Alfred Hospital Department of Dermatology.
Further information can be obtained from Prof. Diona Damian, Department of Dermatology, GH3, Royal Prince Alfred Hospital, Camperdown NSW 2050, telephone: 02 9515 8295, email: email@example.com